Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: Pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

EuroIntervention

Volumn 8, Issue 1, 2012, Pages 87-93

  Hermiller, James B ^a   Sudhir, Krishnankutty ^b   Applegate, Robert J ^c   Rizvi, Ali ^a   Wang, John ^d   Gordon, Paul C ^e   Yaqub, Manejeh ^b   Cao, Sherry ^b   Ferguson, Joanne M ^b   Smith, Robert S ^b   Sood, Poornima ^b   Stone, Gregg W ^f  

^a St Vincent Heart Center of Indiana   (United States)

^b ABBOTT VASCULAR   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^d UNION MEMORIAL HOSPITAL   (United States)

^e MIRIAM HOSPITAL   (United States)

^f Department of Medicine   (United States)

Author keywords

Age; Drug eluting stent; Everolimus; Paclitaxel

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ADULT; AGE; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; Q WAVE; RISK REDUCTION; SMOKING HABIT; STENT THROMBOSIS;

EID: 84865525089     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I1A14     Document Type: Article

References (31)

1. Vlaar PJ, Lennon RJ, Rihal CS, Singh M, Ting HH, Bresnahan JF, Holmes DR, Jr. Drug-eluting stents in octogenarians: early and intermediate outcome. Am Heart J. 2008;155: 680-686.
2. Johnman C, Oldroyd KG, Mackay DF, Slack R, Pell AC, Flapan AD, Jennings KP, Eteiba H, Irving J, Pell JP. Percutaneous coronary intervention in the elderly: changes in case-mix and periprocedural outcomes in 31,758 patients treated between 2000 and 2007. Circ Cardiovasc Interv. 2010;3:341-345.
3. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009;158:520-526 e2.
4. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913.
5. Vencent GK, Velkoff VA. The next four decades, The older population in the United States: 2010 to 2050, Population estimates and projections. US Census Bureau. 2010.
6. Duval R. The retirement effects of old-age pension and early retirement schemes in OECD countries. CEPR/ECB LABOUR MARKET CONFERENCE 2004; Frankfurt, Germany.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, on behalf of the Academic Research Consortium. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351.
8. Hermiller J, Nikolsky E, Lansky A, Applegate R, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone G. Clinical and Angiographic Outcomes of Elderly Patients Treated with Everolimus-Eluting versus Paclitaxel-Eluting Stents: Three-Year Results from the SPIRIT III Randomized Trial. EuroIntervention. 2011;7:307-13.
9. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
10. Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis. 2010;21:46-56.
11. Lange RA, Hillis LD. Second-generation drug-eluting coronary stents. N Engl J Med. 2010;362:1728-1730.
12. Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2010;76: 644-651.
13. De Gregorio J, Kobayashi Y, Albiero R, Reimers B, Di Mario C, Finci L, Colombo A. Coronary artery stenting in the elderly: short-term outcome and long-term angiographic and clinical follow-up. J Am Coll Cardiol. 1998;32:577-583.
14. Munoz JC, Alonso JJ, Duran JM, Gimeno F, Ramos B, Garcimartin I, de la Fuente L, Gomez I, Fernandez-Aviles F. Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome. Am Heart J. 2002;143:620-626.
15. Clark MA, Bakhai A, Lacey MJ, Pelletier EM, Cohen DJ. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. Circulation. 2004;110:259-264.
16. Nasser TK, Fry ET, Annan K, Khatib Y, Peters TF, VanTassel J, Orr CM, Waller BF, Pinto R, Pinkerton CA, Hermiller JB. Comparison of six-month outcome of coronary artery stenting in patients <65, 65-75, and >75 years of age. Am J Cardiol. 1997;80:998-1001.
17. Abizaid AS, Mintz GS, Abizaid A, Saucedo JF, Mehran R, Pichard AD, Kent KM, Satler LF, Leon MB. Influence of patient age on acute and late clinical outcomes following Palmaz-Schatz coronary stent implantation. Am J Cardiol. 2000;85:338-343.
18. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
19. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583.
20. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
21. Hermiller J. Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions. EuroPCR, Paris 2010; http://www.pcronline.com/Lectures/2010/Low- stent-thrombosis-rates-in-5-054-quot-real-world-quot-patients-from-XIENCE-V-USA.
22. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209.
23. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
24. Chinn JA, Sauter JA, Phillips RE, Jr., Kao WJ, Anderson JM, Hanson SR, Ashton TR. Blood and tissue compatibility of modified polyester: thrombosis, inflammation, and healing. J Biomed Mater Res. 1998;39:130-140.
25. Forman DE, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Wei JY, Joshi AA, Dawkins KD, Baim DS. Long-term paclitaxel-eluting stent outcomes in elderly patients. Circ Cardiovasc Interv. 2009;2:178-187.
26. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation. 2003;108:43-47.
27. Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation. 2001;104:773-778.
28. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction - the smoker's paradox revisited. Am Heart J. 2005;150:358-364.
29. Violaris AG, Thury A, Regar E, Melkert R, Serruys PW. Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty. Heart. 2000;84:299-306.
30. Galan KM, Deligonul U, Kern MJ, Chaitman BR, Vandormael MG. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1988;61:260-263.
31. Torguson R, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. Am J Cardiol. 2008;102:1624-1630.